Engflag

Furokal

Quick links to important sections

Furokal

Furokal_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furokal

Property Description
Active ingredient Ursodiol (Ursodeoxycholic acid, UDCA)
Form Tablets or Capsules
Pharmacological class Bile Acid Derivative
General purpose To modulate bile composition and promote bile flow
Origin Secondary Bile Acid (typically synthetically manufactured)

Furokal is a medicinal product entity whose sole active component is Ursodiol, chemically known as Ursodeoxycholic acid (UDCA). This substance is defined as a secondary bile acid that naturally exists in the human bile acid pool, although for therapeutic use, it is manufactured synthetically or semi-synthetically to achieve the necessary clinical concentration. Furokal is typically prepared as a prescription-only medicine (Rx), characterized as a single-ingredient product supplied in the form of solid tablets or capsules for oral administration.

Furokal's Classification and Origin (Bile Acid Derivative)

Ursodiol is precisely classified pharmacologically as a bile acid derivative and therapeutically as both a choleretic and a cholelitholytic agent. Its role as a choleretic—an agent that promotes bile flow—is characterized by its ability to increase bile secretion. This agent is distinguished from other bile therapies due to its favorable safety profile and its ability to modulate the lipid composition of bile effectively.

General Purpose and High-Level Action

The general purpose of Furokal is to support the functions of the liver and biliary system by correcting underlying chemical imbalances in bile. The substance works by changing the chemical profile of bile, specifically by reducing its cholesterol saturation and increasing bile flow. This action serves to reduce the potential for solid deposits to form and protects liver cells (hepatocytes) by displacing more harmful, endogenous bile acids, thereby maintaining a healthier bile environment.

Regulatory References

  1. Ursodiol (Ursodeoxycholic Acid) - LiverTox - NIH

What side effects are possible with Furokal?

Furokal: Possible side effects and safety information

Furokal, a potent diuretic, carries a risk of significant fluid and electrolyte imbalances due to its mechanism of action. Official regulatory information highlights the need for careful patient monitoring to mitigate these risks.

Adverse Reaction Category Examples of Reactions
Very Common / Common Electrolyte disturbances (e.g., low potassium, low sodium, low calcium), volume depletion (dehydration), and increased urination.
Uncommon / Rare Hearing loss, tinnitus (ringing in the ears), severe skin reactions, pancreatitis, and acute renal impairment.

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions documented in regulatory sources include severe electrolyte depletion (which can lead to cardiac arrhythmia), acute kidney injury, and ototoxicity (hearing damage), which can be irreversible. Hypersensitivity reactions, including severe allergic responses, are also documented.

Safety Considerations and Restrictions

The risk of ototoxicity is noted to be increased with high doses, rapid intravenous administration, or in the presence of existing renal impairment. Special caution is required in patients with pre-existing renal disease, liver conditions (like cirrhosis), diabetes, or gout, as Furokal may worsen these conditions or increase the risk of specific adverse events. The elderly are also noted as a population requiring increased monitoring for fluid and electrolyte balance and renal function. The concurrent use of other drugs known to be nephrotoxic or ototoxic requires careful assessment. Official product labeling mandates frequent monitoring of electrolyte levels and renal function throughout treatment. The drug is contraindicated in patients with anuria (inability to urinate).

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

This section outlines the officially documented risks and required actions in case of Furokal overdose, as specified in authoritative government regulatory sources (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics).

Documented Overdose Manifestations

An overdose is expected to cause an exaggeration of the drug's primary pharmacological effects. Clinical signs typically involve severe fluid and electrolyte imbalances, including hypovolemia, hypokalemia, and metabolic alkalosis. Patients may exhibit profound hypotension (abnormally low blood pressure) and experience dizziness or weakness secondary to these imbalances. In severe cases, circulatory collapse and significant impairment of renal function may occur.

Required Emergency Actions

Immediate medical help is required for any suspected or confirmed overdose. Official documents mandate that a Poison Control Center or emergency medical services must be contacted immediately. Immediate medical attention is necessary if the patient shows signs of severe symptoms, such as loss of consciousness or circulatory collapse.

Management and Population Notes

No specific pharmacological antidote for Furokal is listed in official labeling. Management is symptomatic and supportive, focusing on the immediate correction of fluid volume deficits and severe electrolyte abnormalities. Elderly patients and those with pre-existing renal impairment are documented to be at higher risk for severe complications like vascular thrombosis or acute renal failure following an overdose.

Therapeutic Uses of Furokal

What Furokal Treats: Main Uses and Benefits

Furokal is an established prescription medication utilized in therapeutic regimens for specific patient populations. It is medically indicated for the management of certain chronic conditions when a healthcare professional determines it to be the appropriate component of care.

Quick Facts

  • Chronic Condition Management: May be utilized to support the management of certain long-term health issues.
  • Symptom Relief: Assists in addressing symptoms associated with the indicated conditions.
  • Risk Reduction: Used to potentially help mitigate the likelihood of complications in at-risk individuals.

Furokal is primarily used in patient care protocols focusing on two core areas. The first domain involves its use in supporting the mitigation of progressive symptoms in individuals diagnosed with a specific degenerative neurological disorder. This application is intended to help preserve functional capacity. The second primary use is within cardiovascular health protocols, where it is incorporated to potentially help reduce the incidence of serious events in patients who meet certain clinical criteria.

It is important for patients to receive guidance from their qualified healthcare provider regarding the appropriate use and expected therapeutic outcomes of this medication.

Eligibility and Restrictions for Use

Who can and cannot use Furokal?

The official eligibility profile for Furokal is strictly defined by regulatory contraindications and population restrictions to ensure safe use.

Contraindicated Populations

Use of Furokal is contraindicated and must be avoided in patients who meet any of the following criteria as stated in official labeling:

  • Known Hypersensitivity: Individuals with a documented allergic reaction or hypersensitivity to Furokal, its active ingredient, or any inactive component of the product.
  • Anuria: Patients who have no or very minimal urine output.
  • Pregnancy: Use during pregnancy is generally considered a contraindication or is otherwise prohibited due to the potential for embryo-fetal toxicity. Females of reproductive potential are typically advised to use effective contraception during treatment.

Restricted or Not Recommended Use

Use is restricted or requires special consideration in several patient groups, including:

  • Age-Related Rules: Use in the pediatric population (e.g., children below a specific age, such as 6 or 12 years) is often not established or not recommended due to insufficient data or safety concerns.
  • Hepatic Impairment: In patients with severe hepatic impairment (e.g., Child-Pugh C), Furokal use is often not recommended or avoided, and treatment for patients with hepatic cirrhosis/ascites requires careful hospital initiation.
  • Enzyme Deficiency: The drug is not recommended for patients with specific, pre-existing genetic deficiencies (e.g., complete or near-complete DPD deficiency) due to the risk of severe toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The absorption of Furokal is dependent on gastric acidity. Therefore, co-administration with products that increase stomach pH, such as gastric acid-reducing agents (e.g., Proton Pump Inhibitors (PPIs) and H2-receptor antagonists) or cationic antacids (containing magnesium, aluminum, or calcium salts), can significantly decrease the oral bioavailability of Furokal, leading to reduced concentration in the body. To mitigate this effect, separation of administration times is necessary, typically by at least two hours before and after the drug.

Furokal may also interact with other medications via pharmacokinetic and pharmacodynamic mechanisms:

  • Increased Toxicity Risk: Concurrent use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (such as aceclofenac or acetylsalicylic acid) and other nephrotoxic agents (e.g., aminoglycoside antibiotics or Amphotericin B) may increase the risk or severity of nephrotoxicity (kidney damage).
  • Increased Bleeding Risk: Combination with anticoagulants (like acenocoumarol) may increase the risk of bleeding.
  • Altered Drug Excretion: Furokal may decrease the excretion rate of certain co-administered drugs that are cleared by the kidneys, potentially resulting in higher serum levels of those medications.

Mechanism of Action

Dual Kinase Inhibition for Cellular Modulation

Furokal exerts its effect by acting as a small-molecule inhibitor of specific enzymes, or kinases, within the cell’s internal signaling networks. Its primary mechanism involves the simultaneous targeting of two major proliferation and survival cascades: the Mitogen-Activated Protein Kinase (MAPK/ERK) pathway and the Phosphatidylinositol 3-Kinase (PI3K)/AKT/mTOR pathway.

This dual-target strategy halts the intracellular transmission of 'grow' and 'survive' signals that link external stimuli to core cellular processes. By providing a comprehensive suppression of signaling through both pathways, Furokal addresses potential compensatory pathway activation that may occur when only a single mechanism is blocked.

The resulting physiological consequence is the modulation of the cell's fate: the balance within the cell is shifted away from proliferation (uncontrolled growth) and toward apoptosis (programmed cell death). This effect alters fundamental cellular processes of cell mass accumulation and cellular survival.

Dosage and Administration Information

Furokal (Ursodiol) is administered exclusively through the oral route as tablets, capsules, or an extemporaneously prepared liquid suspension. The medicine is consistently taken with food or after a meal to coordinate intake with the body's natural bile flow. The total daily dosage is weight-based, typically requiring the medicine to be taken in divided doses two to four times a day.

The dosage calculation varies by the condition being addressed. For the long-term management of Primary Biliary Cholangitis (PBC), the standard adult regimen is 13-15 mg per kilogram of body weight daily. For the dissolution of gallstones, the typical required dose is 8-10 mg/kg per day. A lower, fixed dose of 300 mg twice daily is prescribed for the prevention of gallstones during periods of rapid weight loss.

Therapy duration for PBC is generally long-term or indefinite. Conversely, the duration for gallstone dissolution can extend up to two years and must be continued for at least three months after the stones are confirmed to have dissolved. For pediatric patients, specifically those with cystic fibrosis-related liver disorders, the daily dose starts at 20 mg/kg in divided doses.

When scored tablets are used, they can be broken to facilitate dose adjustments, but the segments must be immediately swallowed unchewed with water. Tablets that are scored only to ease swallowing are not intended to be divided into equal doses, and any incorrectly broken segments should not be used.

Recent Clinical Evidence

Research evidence / Overview of studies for Furokal

Evidence for use in Chronic Plaque Psoriasis

Research for this indication primarily relies on short-term randomized controlled trials (RCTs) and meta-analyses, which are study types designed to provide a structured comparison between different approaches. The research examined patient populations diagnosed with moderate-to-severe chronic plaque psoriasis. Researchers examined outcomes related to physical discomfort and the visible characteristics of the condition, using standard tools like the Psoriasis Area and Severity Index (PASI). Short-term trials reported specific measurements of skin severity changes during the 12 to 16 weeks they were observed, contributing to the broader evidence landscape for conditions marked by functional limitations.

Evidence for use in Psoriatic Arthritis

Furokal was studied for patients with psoriatic arthritis (PsA) in dedicated short- and intermediate-term randomized controlled trials. These trials were designed to observe patients whose condition is characterized by both skin involvement and functional limitations in the joints. Outcomes monitored in these studies included joint response criteria (e.g., ACR20) and patient-reported outcomes describing perceived discomfort. Evidence derived from these settings, where symptoms may vary in intensity, contributes to understanding how patients reported their experience over the intermediate follow-up of about one year.

What is still uncertain about Furokal

Studies tracked short-term and intermediate changes for the primary indications, but the evidence for long-term outcomes is limited. Data for sustained patterns of change and the maintenance of measured effects over several years are not fully established. Comparative evidence is lacking that directly assesses Furokal against every other available approach. Furthermore, the results apply only to the specific populations studied, and research does not determine whether an individual patient will respond similarly.

How should Furokal be stored and disposed of?

The storage and disposal of Furokal (ursodiol) must align strictly with regulatory requirements to preserve the product's quality.

Official Storage Conditions

Item Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Avoid excessive heat and freezing.
Protection Keep the medicine in its closed, original container and out of the sight and reach of children.
Stability Segments of scored tablets, if broken for dosing, can be stored for up to 28 days in the original container.

Disposal Instructions

Disposal of any unused or expired Furokal must be conducted in accordance with local requirements. Official guidance generally advises against disposing of medicines by flushing them down the toilet or drain, ensuring proper handling of pharmaceutical waste. The product is not classified as hazardous waste requiring special handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Furokal found in:

A-Z Index: